Clinical application progress of immune induction regimen for kidney transplantation
10.3969/j.issn.1674-7445.2021.06.006
- VernacularTitle:肾移植免疫诱导方案临床应用进展
- Author:
Long HE
1
;
Boqian WANG
Author Information
1. Organ Transplantation Center, Northern Theater Command General Hospital of Chinese People's Liberation Army, Shenyang 110000, China
- Publication Type:Research Article
- Keywords:
Kidney transplantation;
Immune induction;
Immunosuppressant;
Rituximab;
Basiliximab;
Alemtuzumab;
Antithymocyte globulin;
Mesenchymal stem cell
- From:
Organ Transplantation
2021;12(6):682-
- CountryChina
- Language:Chinese
-
Abstract:
With the development of immunosuppressants and optimization of immunosuppressive regimens, the survival rates of kidney transplant recipients and grafts have been significantly increased, whereas the incidence of acute rejection and delayed graft function have also been significantly reduced. However, the standard triple immunosuppressive regimen (calcineurin inhibitor+antimetabolite+glucocorticoid) still cannot effectively control the rejection of transplant kidney. Consequently, immune induction before transplantation has been proposed. Immune induction therapy may delay the application time and reduce the dosage of calcineurin inhibitor, lower the incidence of short-term acute rejection after operation, and improve the middle- and long-term prognosis of the recipients. In this article, research progresses on monoclonal antibody-based immune induction regimen, polyclonal antibody-based immune induction regimen and mesenchymal stem cell-based immune induction regime were investigated, aiming to provide reference for optimizing the immune induction regime for kidney transplantation.
